Litigation Details for Pharmacyclics LLC v. BeiGene USA, Inc. (D. Del. 2023)
✉ Email this page to a colleague
Pharmacyclics LLC v. BeiGene USA, Inc. (D. Del. 2023)
Docket | ⤷ Try a Trial | Date Filed | 2023-06-13 |
Court | District Court, D. Delaware | Date Terminated | |
Cause | 35:271 Patent Infringement | Assigned To | Colm Felix Connolly |
Jury Demand | Plaintiff | Referred To | |
Patents | 10,016,435; 10,478,439; 9,801,881 | ||
Link to Docket | External link to docket |
Small Molecule Drugs cited in Pharmacyclics LLC v. BeiGene USA, Inc.
Details for Pharmacyclics LLC v. BeiGene USA, Inc. (D. Del. 2023)
Date Filed | Document No. | Description | Snippet | Link To Document |
---|---|---|---|---|
2023-06-13 | 1 | Complaint | Book for IMBRUVICA®, including U.S. Patent Nos. 9,801,881; 10,016,435; 10,478,439; 10,653,696; and 10,751,342…9,801,881; 10,016,435; 10,478,439; 10,653,696; and 10,751,342. Moreover, on information and belief, BeiGene…BTK inhibitors, including U.S. Patent No. 11,672,803 (the “’803 Patent”), which is asserted in this action… THE PATENT IN SUIT 12. On June 13, 2023, the United States Patent and Trademark…the ’803 Patent. 27. Upon information and belief, during the term of the ’803 Patent, BeiGene | External link to document |
>Date Filed | >Document No. | >Description | >Snippet | >Link To Document |